page 1 page 2 page 3 page 4 page 5 page 6 page 7 page 8 page 9 page 10 page 11 page 12 page 13 page 14 page 15 page 16 page 17 page 18 page 19 page 20 page 21 page 22 page 23 page 24 page 25 page 26 page 27 page 28 page 29 page 30 page 31 page 32 page 33 page 34 page 35 page 36 page 37 page 38 page 39 page 40 page 41 page 42 page 43 page 44 page 45 page 46 page 47 page 48 page 49 page 50 page 51 page 52 page 53 page 54 page 55 page 56 page 57 page 58 page 59 page 60 page 61 page 62 page 63 page 64 page 65 page 66 page 67 page 68 page 69 page 70 page 71 page 72 page 73 page 74 page 75 page 76 page 77 page 78 page 79 page 80 page 81 page 82 page 83 page 84 page 85 page 86 page 87 page 88 page 89 page 90 page 91 page 92 page 93 page 94 page 95 page 96 page 97 page 98 page 99 page 100 page 101 page 102 page 103 page 104 page 105 page 106 page 107 page 108 page 109 page 110 page 111 page 112 page 113 page 114 page 115 page 116 page 117 page 118 page 119 page 120 page 121 page 122 page 123 page 124 page 125 page 126 page 127 page 128 page 129 page 130 page 131 page 132 page 133 page 134 page 135 page 136 page 137 page 138 page 139 page 140 page 141 page 142 page 143 page 144 page 145 page 146 page 147 page 148 page 149 page 150 page 151 page 152 page 153 page 154 page 155 page 156 page 157 page 158 page 159 page 160 page 161 page 162 page 163 page 164 page 165 page 166 page 167 page 168 page 169 page 170 page 171 page 172 page 173 page 174 page 175 page 176 page 177 page 178 page 179 page 180 page 181 page 182 page 183 page 184 page 185 page 186
|
National Innovation Centre www. nic. nhs. uk If the life science and health-care technology industries are to make a major contribution to the future wealth of the UK, then it is imperative that the business of innovating in those fields is managed. Lord Darzi, former Minister for Health, and Lord Drayson, Minister for Science and Inno-vation at BIS, are agreed that we can no longer afford to leave innovation to chance. An educated public together with a weak economy are demand-ing quality healthcare and the highest standard of associated products - and all for the same price or less. Historically, leaving NHS innova-tion to chance resulted in good innovations never seeing the light of day or, if they made it, a slow take-up of ideas, or, worse still, devel-opment go-ing overseas so that IP haemorrhaged from the UK. The current pan- government em-phasis on life sciences places a responsibility on the healthcare technology industry to become one of the future pillars of UK GDP and deliver economic value from its innovations. Managing the innovation process But this commercial approach to healthcare innovation isn't new to one NHS organisation. Two years ago, the National Innovation Cen-tre ( NIC) embraced this joint policy agenda and has already delivered some startling results. Working with products in the pre- market stage, they are committed to the strategy of ' managing innova-tion'. Brian Winn, who heads the NIC, says: " We leave the creativity to the innovator, but we manage the process of making an idea a reality. The key success factors are to identify a genuine and impor-tant enough need, to manage the growth of the solution, show that it works in the real world and then to share it." In a nutshell, the NIC helps innovators by providing an infrastruc-ture to support all of those key factors. Identifying a genuine and important enough need As a rule, human nature propels us towards solutions to problems, without first testing the impor-tance of the need. The UK's 2,000 life sciences SMEs will tell you that their job would be straightfor-ward, not to mention more prof-itable, if only they could receive clearly articulated needs from the NHS. As it is, most suppliers de-sign and develop in the dark and hope that their products hit the spot. Sadly, too many healthcare innovations are left sitting on the proverbial shelf. In response to this problem, the NIC has teamed up with the Technology Strategy Board ( TSB) to harness ' statements of need' from practising NHS clinicians. These are posted onto the NIC website - http:// clinicalneed. nic. nhs. uk/ - and commercial suppli-ers can then respond. Some can partner an NHS Trust and apply to the local SHA to access the new innovation funds, or they can go to the NIC who will also give fi-nancial support to develop select-ed solutions. The clinical needs come from across the healthcare spectrum. Current examples in-clude a need for a means to align bone screws with pelvic anatomy in Orthopaedic surgery and a need for an alternative method of foetal monitoring in problem pregnancies. Another route to developing in-novation is through a process known as ' Wouldn't It Be Great If.' ( WIBGI). This approach charges teams from industry and the NHS to identify both their clinical needs and the potential technology solutions. The NIC's approach was first applied to Or-thopaedics ( knee and hip surgery) to support delivery of the 18- week programme. Professor Sue Hill and Paul Griffiths managed the process for DH's 18- week pro-gramme, and used the approach to bring together both practising NHS professionals and industry to look at clinical needs. Nurses, physiotherapists, surgeons, indus-try and policy makers went on to select 5 high- impact technologies that they felt would have a ma-jor impact on reducing waiting lists. Professor Hill said: " It seems another age now, but in 2007, cracking the long waiting lists in Orthopaedics was a huge chal-lenge. I felt the clinical community in Orthopaedics knew the prob-lems and many of the answers, and the WIBGI approach allowed us to get to those." " The NHS should anticipate and respond to the challenges of the fu-ture." Lord Darzi, High Quality Care for All, June 2008. A multi- disciplinary approach to identifying needs and solutions helped reduce Orthopaedic waiting lists. " The key success factors to realising the value in innovations are identifying a genuine and important enough need, managing the growth of the solution, showing that it works in the real world and then sharing it." Brian Winn, National Innovation Centre. INNOVATION UK HEALTHCARE More recently, the WIBGI ap-proach was applied to the DH's Healthcare Acquired Infection programme ( HCAI). With HCAIs costing the NHS over £ 1 billion a year, the ' needs based' approach again brought the NHS, industry and design experts together to look at cross- infection issues and jointly develop solutions. Based on an ' open innovation' model, the approach overcame tradi-tional barriers by working more closely with industry and directly linking health need to technology supply. The aim was to get prod-ucts designed, developed and in place so that they could benefit patients as quickly as possible. The result was 17 new product designs in as many months - a significantly faster solution than the traditional approach of wait-ing for the market to develop new products and then procure and implement them. Open Innovation platforms The NIC is currently using its novel approach in six other ar-eas - Blood Donation, Paediatrics, Urology, Ambulance Services, Heart Failure and Regenerative Medicine. Again working in part-nership with the TSB, the NIC brought together clinical teams from each of the disciplines to first identify the needs. At sub-sequent meetings, NHS, industry and academia came together to outline the desired solutions, the business opportunities they might present and other requirements that might be needed to bring the concept to market. By using an ' open innovation' approach, the silos that are usually created around IP ownership, product de-velopment and procurement were avoided and all parties were able to focus their efforts on the out-come required. Managing the growth of the solution All of the WIBGI outcomes are now posted on the NIC website http:// competitions. nic. nhs. uk/ ChallengeList. aspx so that exter-nal suppliers can apply to address the needs. The NIC expects that some of the solutions will be met by industry with minimum input; others will demand more support from the NIC who will work with external suppliers to develop so-lutions to the articulated needs. NIC will provide financial support to help commercial companies either develop ideas unilaterally or in collaboration with others. This is a structured process that involves the NIC liaising along the way with the NHS Supply Chain to support ultimately the take- up of the products across the NHS. A temporary isolation unit and improved handwashing procedures were amongst 17 ideas that are in development to control the spread of Healthcare Acquired Infections. Clinicians, academics, industrialists and designers from across the innovation spectrum came together at the WIBGI innovation work-shops at ExCel in June to outline solutions to clinically identified need. The NIC will now take a dozen ideas forward for further de-velopment. |